Research Progress of Molecular Classification Guiding Targeted Therapy Combined with Fertility-Preserving Treatment for Endometrial Cancer

In recent years, the incidence of endometrial cancer has continued to increase and tends to be younger. An increasing number of young patients wish to preserve reproductive function during treatment. Although progestin therapy has a high remission rate, some patients experience hormone resistance, recurrence, or even disease progression, making this traditional treatment unsuitable for everyone. Molecular classification can effectively guide treatment and provide prognostic evaluations for endometrial cancer, but its clinical application in fertility-preserving treatment remains unclear. This article will review the role of molecular classification in endometrial cancer care and explores the potential value of combining targeted therapies with traditional treatments. The goal is to provide new strategies and insights for fertility-preserving treatment and management of endometrial cancer in the era of precision medicine.